Yale SPORE in Lung Cancer News

A listing of recent publications by Yale Cancer Center researchers and clinicians in the first quarter of 2024

Members of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center joined more than 11,000 physicians, scientists, and trainees focused on advancing research and clinical care in breast cancer attending the annual San Antonio Breast Cancer Symposium December 10-14, 2024. The Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease to an international audience of academic and private physicians and researchers.

Melanie Morrill received a diagnosis of metastatic ALK+ lung cancer at age 50, and at the time the disease came with a life expectancy of 3-6 years. However, in the last ten years, advances and progress in lung cancer research have transformed what was a terminal diagnosis into a chronic disease controlled with oral medication.

Thazin Nwe Aung, PhD, Associate Research Scientist in Pathology, has been selected for a Patterson Mentored Research Award. Dr. Aung is a member of the Rimm Lab, and her mentor is David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology and of Medicine (Medical Oncology).

Yale Cancer Center and Smilow Cancer Hospital people who have been honored

The study by Yale Cancer Center (YCC) researchers at Yale School of Medicine (YSM) discovered that not all CD8+ T cells are allies in a body’s fight against cancer cells. In a new study, patients living with severe melanoma who had increased levels of suppressor, regulatory CD8+ T cells had worse survival outcomes.

Yale Cancer Center experts will discuss a variety of topics at SABCS ranging from novel therapeutics for HER2+ breast cancers, dosing optimization in breast cancer trials, and new findings on different genomic ancestries for advanced breast cancers.

The American Lung Association just dropped its State of Lung Cancer report. The data looks at how lung cancer varies by state. How did Connecticut fare? Dr. Roy Herbst, deputy director, lung cancer physician, and expert at Yale Cancer Center gave us some key takeaways for our state.

Dr. Roy S. Herbst, MD, PhD received the 2024 Ezra Greenspan Award from The Chemotherapy+ Foundation at a gala in New York Nov. 19, 2024. He is a deputy director of the Yale Cancer Center and Chief of Hematology/Medical Oncology, YCC and Smilow Cancer Hospital; Assistant Dean for Translational Research, Yale School of Medicine; Program Director, Master of Health Science—Clinical Investigation Track (MHS-CI)